Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Italfarmaco Spa maintains a presence in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 2 pending office actions, showing active interaction with the patent office. These actions are both located within 1 distinct art unit. This concentration suggests that the pending matters, while multiple, are technically related and subject to the specific examination standards of that 1 art unit.
The prosecution is split between 2 distinct examiners, which introduces different viewpoints into the review of the portfolio. DAVID PAUL BOWLES is identified as the busiest examiner, currently managing 1 pending office action. Given that there are 2 pending actions in total, the workload is divided between the 2 examiners. This distribution requires the applicant to manage 2 separate examiner relationships simultaneously while operating within the 1 technical art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOWLES, DAVID PAUL | 1 | 72.7% | +22.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18721923 | USE OF SOMATOSTATIN AGONIST IN THE TREATMENT OF SSTR3 EXPRESSING TUMORS | BOWLES, DAVID PAUL | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18721923 | USE OF SOMATOSTATIN AGONIST IN THE TREATMENT OF SSTR3 EXPRESSING TUMORS | BOWLES, DAVID PAUL | — | §102§103§112DP | Non-Final OA | — | Pending | Jun 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial